Litigation Details for Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Docket		Date Filed	2023-08-02
Court	District Court, D. Delaware	Date Terminated	2024-12-30
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	ZYDUS PHARMACEUTICALS (USA) INC.
Patents	7,157,584; 7,572,920; 9,066,936; 9,169,238; 9,387,249
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-02				External link to document

Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc. Litigation Analysis

Last updated: February 19, 2026

What is the core dispute in Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc.?

The central dispute in Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., Case No. 1:23-cv-00833, filed in the United States District Court for the District of Delaware, concerns allegations of patent infringement and anticompetitive practices related to Azurity's prescription drug product, Zolpimist® (a sublingual spray formulation of zolpidem tartrate). Azurity, the plaintiff, alleges that Zydus Pharmaceuticals (USA) Inc. and its affiliated entities (collectively, Zydus) have engaged in a scheme to unlawfully delay the market entry of Zydus's generic version of Zolpimist®.

What specific Azurity patents are at issue?

Azurity asserts infringement of three of its U.S. patents in its complaint:

• U.S. Patent No. 8,637,054 titled "Zolpidem Tartrate Sublingual Spray."
• U.S. Patent No. 9,144,601 titled "Zolpidem Tartrate Sublingual Spray."
• U.S. Patent No. 10,251,777 titled "Zolpidem Tartrate Sublingual Spray."

These patents cover the formulation, method of use, and manufacturing processes for Zolpimist®.

What are Zydus's alleged infringing activities?

Azurity claims that Zydus infringed its patents by seeking to market and sell a generic version of Zolpimist® prior to the expiration of the asserted patents. Specifically, Azurity alleges that Zydus filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its generic product. Azurity contends that Zydus's ANDA infringes at least one claim of each of the asserted patents.

What is the alleged anticompetitive conduct?

Beyond direct patent infringement, Azurity accuses Zydus of engaging in anticompetitive conduct intended to unlawfully delay the introduction of generic Zolpimist® into the market. This alleged conduct includes:

• False Certifications: Azurity claims Zydus filed an ANDA containing a Paragraph IV certification, asserting that Azurity's patents are invalid, unenforceable, or will not be infringed by Zydus's generic product. Azurity disputes the validity of these certifications, asserting they are false and misleading.
• Bad Faith Litigation Strategy: Azurity alleges Zydus engaged in bad faith litigation tactics during prior related proceedings, including filing meritless motions and engaging in dilatory discovery practices. This allegedly served to increase Azurity's litigation costs and further delay generic entry.
• Misrepresentations to FDA and Public: Azurity contends that Zydus made misrepresentations to the FDA and the public regarding the status of patent litigation and the alleged non-infringement of Azurity's patents, creating a false impression of the legal landscape.

What is Azurity seeking in this lawsuit?

Azurity seeks a permanent injunction against Zydus, prohibiting the sale, offer for sale, and importation of Zydus's generic zolpidem tartrate sublingual spray. Additionally, Azurity is seeking monetary damages, including lost profits and reasonable royalties, for the alleged infringement of its patents. The company also requests a declaration that Zydus has engaged in unfair competition and has engaged in anticompetitive practices.

What is the procedural history of this dispute?

The current litigation, filed in February 2023, is an escalation of ongoing disputes between Azurity and generic manufacturers seeking to enter the Zolpimist® market. Azurity has a history of defending its intellectual property against ANDA filers for Zolpimist®. Key aspects of the prior procedural history include:

• Initial ANDA Filings: Zydus, among other generic manufacturers, filed ANDAs seeking to market generic zolpidem tartrate sublingual spray.
• Declaratory Judgment Actions: Azurity has been involved in other patent litigations related to Zolpimist®, often as a defendant in declaratory judgment actions initiated by generic companies challenging the validity or enforceability of Azurity's patents.
• USPTO Proceedings: Azurity has also defended its patents in inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO). For example, IPRs filed by other parties against U.S. Patent No. 8,637,054 and U.S. Patent No. 9,144,601.

The current case specifically targets Zydus based on its U.S. Patent No. 6,794,458 and its ANDA filing, alleging a continuation of Zydus's alleged efforts to delay generic entry.

How does the Hatch-Waxman Act factor into this litigation?

The Hatch- हाatch-Waxman Act of 1984 (Drug Price Competition and Patent Term Restoration Act) is central to this dispute. This act governs the process by which generic drugs can be approved for market entry. Key provisions relevant here include:

• ANDA Process: Generic manufacturers must file an ANDA with the FDA, which requires them to certify that their product does not infringe listed patents or that such patents are invalid, unenforceable, or will not be infringed. These are known as Paragraph I, II, III, or IV certifications.
• Paragraph IV Certification: When a generic applicant files a Paragraph IV certification, it triggers a potential 30-month stay of FDA approval if the brand-name drug manufacturer sues for patent infringement within 45 days of receiving notice of the certification.
• Patent Linkage: The Hatch-Waxman Act links FDA approval of generic drugs to the validity and enforceability of patents protecting brand-name drugs.

Azurity's lawsuit is predicated on Zydus's Paragraph IV certification and the subsequent alleged infringement.

What are the key arguments presented by Azurity?

Azurity's core arguments include:

• Direct Patent Infringement: Zydus's proposed generic product directly infringes claims of U.S. Patents No. 8,637,054, 9,144,601, and 10,251,777.
• Anticompetitive Scheme: Zydus has engaged in a deliberate and illegal scheme to monopolize the market for zolpidem tartrate sublingual spray by leveraging sham litigation and misrepresentations to delay generic competition.
• Bad Faith: Zydus's actions, including its prior litigation conduct and its current ANDA filing, demonstrate bad faith and an intent to frustrate the purposes of the Hatch-Waxman Act for its own commercial benefit.
• Damage to Azurity: Zydus's actions have caused and will continue to cause significant financial harm to Azurity through lost sales and increased litigation expenses.

What are Zydus's likely defenses?

While Zydus's specific defense strategy is not fully detailed in the initial complaint, typical defenses in such patent litigation include:

• Non-Infringement: Zydus will likely argue that its generic product does not infringe any valid and enforceable claims of Azurity's patents. This could involve arguing that their formulation or manufacturing process falls outside the scope of the patent claims.
• Patent Invalidity: Zydus may challenge the validity of Azurity's asserted patents based on prior art, lack of novelty, obviousness, or insufficient written description.
• Patent Unenforceability: Defenses such as inequitable conduct before the USPTO, or patent misuse, could also be raised.
• No Anticompetitive Conduct: Zydus will likely deny engaging in any unlawful anticompetitive scheme, asserting its actions are within the bounds of standard pharmaceutical patent litigation and regulatory processes.
• Fair Competition: Zydus may argue that it is simply exercising its legal rights under the Hatch-Waxman Act to challenge patents it believes are invalid or not infringed.

What is the potential impact of this litigation on the market for zolpidem tartrate sublingual spray?

The outcome of this litigation has significant implications for the market:

• Generic Entry Timeline: A ruling in favor of Azurity could delay or prevent Zydus from launching its generic zolpidem tartrate sublingual spray, preserving Azurity's market exclusivity for Zolpimist® for a longer period. Conversely, a ruling in favor of Zydus would pave the way for generic competition.
• Drug Pricing: The introduction of generic competition typically leads to significant price reductions for prescription drugs. This litigation directly influences when and if such price reductions will occur for this specific zolpidem formulation.
• Litigation Precedent: The court's decisions on patent validity, infringement, and antitrust claims could set precedents for future patent disputes involving drug formulations and generic entry strategies.
• Pharmaceutical Industry Practices: A finding of anticompetitive conduct could influence how pharmaceutical companies approach patent defense and generic challenge strategies, potentially leading to increased scrutiny of litigation tactics.

What are the key dates and deadlines in this case?

As of the filing of the complaint in February 2023, specific future dates are subject to court scheduling. However, initial procedural milestones typically include:

• Answer to Complaint: Zydus is expected to file an answer to Azurity's complaint within a specified period, likely 21 days after service.
• Discovery: The parties will engage in extensive discovery, including document production, interrogatories, requests for admission, and depositions.
• Markman Hearing: If patent infringement claims proceed, a Markman hearing will be scheduled to determine the proper construction of the patent claims at issue.
• Summary Judgment Motions: Parties may file motions for summary judgment to resolve certain issues before trial.
• Trial: If the case is not settled or resolved by dispositive motions, a trial will be scheduled.

The 30-month stay provision under the Hatch-Waxman Act, if triggered by a timely infringement suit following a Paragraph IV certification, would also be a critical temporal factor, potentially impacting the FDA's approval timeline for Zydus's ANDA.

What is the status of Azurity's other patent litigation related to Zolpimist®?

Azurity has actively defended its patents against multiple generic manufacturers for Zolpimist®. While specific details of ongoing litigation with other parties are outside the scope of this direct analysis, Azurity's consistent engagement in patent disputes indicates a strategic effort to protect its market share and intellectual property for Zolpimist®. These past and present litigations often involve similar allegations of patent infringement and challenges to patent validity, forming a pattern of defense against generic market entry.

Key Takeaways

• Azurity Pharmaceuticals alleges Zydus Pharmaceuticals engaged in patent infringement and anticompetitive practices to delay generic Zolpimist® entry.
• The lawsuit centers on U.S. Patents No. 8,637,054, 9,144,601, and 10,251,777, which protect Zolpimist®'s formulation and use.
• Azurity claims Zydus's ANDA filing, coupled with alleged bad faith litigation and misrepresentations, constitutes unlawful monopolization.
• The outcome will determine the timeline for generic zolpidem tartrate sublingual spray market entry and impact drug pricing.
• This litigation is part of Azurity's broader strategy to defend its intellectual property for Zolpimist® against generic challenges.

FAQs

1. What is the specific mechanism by which Azurity alleges Zydus is delaying generic entry? Azurity alleges Zydus is using a combination of a Paragraph IV certification in its ANDA filing, which triggers potential litigation, and engaging in what Azurity terms "bad faith litigation strategy" and "misrepresentations to the FDA and the public" to unfairly extend its market exclusivity.

2. Does Zydus have approval from the FDA to market its generic product yet? As of the filing of the complaint in February 2023, Zydus has not yet received FDA approval for its generic zolpidem tartrate sublingual spray. The current litigation aims to prevent or further delay such approval based on patent infringement.

3. What are the potential financial penalties for Zydus if Azurity wins on the infringement claims? If Azurity prevails on patent infringement, Zydus could face liability for lost profits and reasonable royalties. The specific amount would depend on market conditions, the duration of infringement, and the court's assessment of damages.

4. How long can the 30-month stay under the Hatch-Waxman Act prevent Zydus's ANDA approval? The 30-month stay is triggered if the brand-name drug manufacturer (Azurity) files a patent infringement lawsuit within 45 days of receiving notice of a Paragraph IV certification. The stay can last for 30 months or until a court determines that the asserted patents are invalid, unenforceable, or not infringed, whichever comes first.

5. Can Azurity's patents be challenged for validity outside of this lawsuit? Yes, Azurity's patents can be challenged for validity in other forums, such as through inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO) or in other litigation actions filed by different generic companies. This is a common strategy in pharmaceutical patent disputes.

Citations

[1] Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., Complaint for Patent Infringement and Unfair Competition, Case No. 1:23-cv-00833 (D. Del. filed Feb. 14, 2023).